Drug intelligence / Profile preview

nPT-ery

Development stage: Preclinical
Lead developer: GSK
Modality: RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules

Overview

nPT-ery is a program comprising anti-inflammatory erythromycin analogues, developed by Biotica Technology in partnership with GSK. These compounds are macrolide antibiotics specifically engineered to treat inflammatory diseases by leveraging the anti-inflammatory and immunomodulatory actions of erythromycin, which are distinct from its antibacterial activity. The program aims to discover, develop, and commercialize novel erythromycin-based macrolides.

Targets

IL8 (C-X-C Motif Chemokine Ligand 8)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on nPT-ery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nPT-ery.

Explore the full profile